iBio announces advancement on COVID-19 vaccine development
iBio currently trades at $1.39 and has seen gains of 239% in the past month. iBio has seen a decrease in revenue in the past four quarters. Recently, iBio announced that immunization studies for its SARS-CoV-2 Virus-Like Particle (“VLP”) program (“IBIO-200”) are proceeding at Texas A&M University System (“TAMUS”) laboratories. The work is being performed as part of the Master Joint Development Agreement established between iBio and TAMUS in 2016. This makes iBio a because “This next stage of work on IBIO-200 is critically important as we seek to quickly enter the clinic with one of our VLP candidates,” said Tom Isett, Co-Chairman & Chief Executive Officer of iBio. “As we optimize our choice of adjuvants with both VLP types we have developed, we are fortunate to have a strong relationship with TAMUS that allows us to rapidly bring their deep insight into the pathogenesis of coronaviruses and experience with vaccine development to the task.”. This makes iBio a great buy. iBio’s dividends sit at 0% and has a market cap of $113.62 million. Overall, iBio is a stock you want to keep an eye out for. Yesterday the stock closed at 1.12 leaving investors up 7.55% in the past 24 hours. iBio’s high 1-year forecast is 30 with a low of 30.
Based on the price ($1.39) and gains over the past month gains of 239% this stock should be a winner in the upcoming month.